Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Invested Capital (2019 - 2025)

Silence Therapeutics' Invested Capital history spans 7 years, with the latest figure at $62.3 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 53.51% year-over-year to $62.3 million; the TTM value through Dec 2025 reached $62.3 million, down 53.51%, while the annual FY2025 figure was $62.3 million, 53.51% down from the prior year.
  • Invested Capital for Q4 2025 was $62.3 million at Silence Therapeutics, down from $74.1 million in the prior quarter.
  • Across five years, Invested Capital topped out at $156.8 million in Q1 2024 and bottomed at $11.5 million in Q4 2021.
  • The 5-year median for Invested Capital is $94.2 million (2025), against an average of $87.4 million.
  • The largest annual shift saw Invested Capital soared 533.33% in 2024 before it crashed 53.51% in 2025.
  • A 5-year view of Invested Capital shows it stood at $11.5 million in 2021, then skyrocketed by 125.26% to $25.9 million in 2022, then decreased by 18.26% to $21.2 million in 2023, then skyrocketed by 533.33% to $134.0 million in 2024, then plummeted by 53.51% to $62.3 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Invested Capital are $62.3 million (Q4 2025), $74.1 million (Q3 2025), and $94.2 million (Q2 2025).